List view / Grid view
Researchers have produced a mathematical framework enabling quick assessment of how different parameters control interactions between molecules with multiple binding sites.
A new study has demonstrated for the first time that mutations that affect myosin motor activity result in slower cell movements in vivo.
Researchers have used whole genome sequencing to analyse breast cancers and reveal which are more responsive to treatments, which could improve the development of oncologic therapies.
There is still much to be done regarding how training is delivered and monitored in core technologies such as flow cytometry. Here, Derek Davies outlines the approaches his team at The Francis Crick Institute are taking to train users of such technologies to ensure quality data is obtained and best…
As research moves forward at a rapid pace and data is being generated in larger quantities than ever before, one problem the scientific community faces is reproducibility.
New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors, have revolutionised cancer treatment.
Antisense oligonucleotides are an emerging therapeutic option for treating diseases with known genetic origin.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
An algorithm has been developed which can predict the outcomes of complex chemical reactions with over 90 percent accuracy which can be applied to drug development.
With the recent rise in the prevalence of celiac disease, monitoring gluten levels in food and beverage has become increasingly important as more people strive to avoid gluten.
Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
Sartorius debuts their new product, the Intellicyt iQue3, at this year's CYTO® conference and exhibition.
From the world’s flagship neutron science facility, Institut Laue-Langevin (ILL), Matthew Blakeley shares insights into how they are harnessing the power of neutrons to aid their search for new cancer treatments.
Researchers prove it's possible to control a visual behaviour of a mouse by activating neurons in its visual cortex.
Native mass spectrometry has the potential to be a fast, simple, highly sensitive and automatable technique for compound screening in drug design and discovery. In this article, Rod Chalk and Nicola Burgess-Brown discuss the key attributes of native mass spectrometry and reasons why it is not yet widely employed.
